Pharmacology of "atypicality" of antipsychotic drugs: Status and perspective

Archives of Psychiatry and Psychotherapy

Volumn 12, Issue 4, 2010, Pages 5-11

  Newman Tancredi, Adrian ^a   Kleven, Mark S ^b  

^a NeuroAct Communication   (France)

^b NONE   (United States)

Author keywords

5 HT1A receptors; Antipsychotic; D2 receptors; Schizophrenia

Indexed keywords

ADOPRAZINE; ARIPIPRAZOLE; ASENAPINE; ATYPICAL ANTIPSYCHOTIC AGENT; BIFEPRUNOX; CARIPRAZINE; CHLORPROMAZINE; CLOZAPINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; F 15063; HALOPERIDOL; LURASIDONE; OLANZAPINE; PALIPERIDONE; PEROSPIRONE; PF 217830; QUETIAPINE; RISPERIDONE; SEROTONIN 1A AGONIST; SEROTONIN 1A RECEPTOR; SEROTONIN 2A ANTAGONIST; SERTINDOLE; SSR 181507; UNCLASSIFIED DRUG; ZIPRASIDONE;

COGNITIVE DEFECT; DOPAMINERGIC TRANSMISSION; DRUG MECHANISM; EXTRAPYRAMIDAL SYMPTOM; HEART ARRHYTHMIA; HUMAN; METABOLIC DISORDER; NONHUMAN; PREFRONTAL CORTEX; RECEPTOR UPREGULATION; REVIEW; SIDE EFFECT; WEIGHT GAIN;

EID: 79952787886     PISSN: 15092046     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Rossler W, et al. Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol. 2005; 15(4): 399-409. (Pubitemid 40943544)
2. Meltzer HY, and Huang M. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems. Prog Brain Res. 2008; 172: 177-97.
3. Goff DC, and Shader RI. Non-neurological side-effects of antipsychotic drugs. In: Hirsch SR, Weinberger D. editors. Schizophrenia. Oxford: Blackwell Publishing; 2003. 573-588.
4. Ichikawa J, Meltzer HY. Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs. Eur Arch Psychiatry Clin Neurosci. 1999; 249(Suppl 4): 90-8.
5. Lahti AC, et al. Functional effects of antipsychotic drugs: comparing clozapine with haloperidol. Biol Psychiatry. 2003; 53(7): 601-8. (Pubitemid 36385062)
6. Richtand NM, et al. Role of serotonin and dopamine receptor binding in antipsychotic efficacy. Prog Brain Res. 2008; 172: 155-75.
7. Roth BL, Sheffler DJ, Kroeze WK. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov. 2004; 3(4): 353-9. (Pubitemid 38499762)
8. Reynolds GP, Kirk SL. Metabolic side effects of antipsychotic drug treatment-pharmacological mechanisms. Pharmacol Ther. 2010; 125(1): 169-79.
9. Tamminga CA, Carlsson A. Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis. Curr Drug Targets CNS Neurol Disord. 2002; 1(2): 141-7.
10. Newman-Tancredi A, Cussac D, Depoortere R. Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third-generation antipsychotics. Curr Opin Investig Drugs. 2007; 8(7): 539-54. (Pubitemid 47016322)
11. Newman-Tancredi A. The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives. Curr Opin Investig Drugs. 2010; 11(7): 802-12.
12. Assie MB, et al. Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain. J Pharmacol Exp Ther. 2005; 315(1): 265-72.
13. Rollema H, et al. Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation. Eur J Pharmacol. 1997; 338(2): 3-5.
14. Burnet PW, Eastwood SL, Harrison PJ. [3H]WAY-100635 for 5-HT1A receptor autoradiography in human brain: a comparison with [3H]8-OH-DPAT and demonstration of increased binding in the frontal cortex in schizophrenia. Neurochem Int. 1997; 30(6): 565-74. (Pubitemid 27187227)
15. Tauscher J, et al. Brain serotonin 5-HT(1A) receptor binding in schizophrenia measured by positron emission tomography and [11C]WAY-100635. Arch Gen Psychiatry. 2002; 59(6): 514-20.
16. Czyrak A, et al. Serotonin 5-HT1A receptors might control the output of cortical glutamatergic neurons in rat cingulate cortex. Brain Res. 2003; 989(1): 42-51. (Pubitemid 37281400)
17. Wedzony K, et al. Single doses of MK-801, a non-competitive antagonist of NMDA receptors, increase the number of 5-HT1A serotonin receptors in the rat brain. Brain Res. 1997; 756(1-2): 84-91. (Pubitemid 27241611)
18. Calcagno E, Carti M, Invernizzi RW. The 5-HT(1A) receptor agonist 8-OH-DPAT prevents prefrontocortical glutamate and serotonin release in response to blockade of cortical NMDA receptors. J Neurochem. 2006; 96(3): 853-60.
19. Invernizzi RW, Cervo L, Samanin R. 8-Hydroxy-2-(di-n-propylamino) tetralin, a selective serotonin1A receptor agonist, blocks haloperidol-induced catalepsy by an action on raphe nuclei medianus and dorsalis. Neuropharmacology. 1988; 27(5): 515-8.
20. Kleven MS, et al. Novel antipsychotic agents with 5-HT(1A) agonist properties: role of 5-HT(1 A) receptor activation in attenuation of catalepsy induction in rats. Neuropharmacology. 2005; 49(2): 135-43. (Pubitemid 40933752)
21. Prinssen EP, Colpaert FC, Koek W. 5-HT1A receptor activation and anti-cataleptic effects: high-efficacy agonists maximally inhibit haloperidol-induced catalepsy. Eur J Pharmacol. 2002; 453(2-3): 217-21. (Pubitemid 35223513)
22. Heusler P, et al. Antipsychotics differ in their ability to internalise human dopamine D2S and human serotonin 5-HT1A receptors in HEK293 cells. Eur J Pharmacol. 2008; 581(1-2): 37-46.
23. Newman-Tancredi A, et al. Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia. Int J Neuropsychopharmacol. 2005; 8(3): 341-56. (Pubitemid 41002489)
24. Millan MJ, et al. S16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: II. Functional profile in comparison to clozapine and haloperidol. J Pharmacol Exp Ther. 1998; 286(3): 1356-73.
25. Depoortere R, et al. F15063, a compound with D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties. III. Activity in models of cognition and negative symptoms. Br J Pharmacol. 2007; 151(2): 266-77. (Pubitemid 46763037)
26. Hagiwara H, et al. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antipsychotic drug perospirone: role of serotonin 5-HT1A receptors. Eur Neuropsychopharmacol. 2008; 18(6): 448-54.
27. Nagai T, et al. Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors. Psychopharmacology. 2009; 202(1-3): 315-28.
28. Meltzer HY, Sumiyoshi T. Does stimulation of 5-HT(1A) receptors improve cognition in schizophrenia? Behav Brain Res. 2008; 195(1): 98-102.
29. Lawrence AJ. Optimisation of anti-psychotic therapeutics: a balancing act? Br J Pharmacol. 2007; 151(2): 161-2.
30. Bruins Slot LA, Kleven MS, Newman-Tancredi A. Effects of novel antipsychotics with mixed D(2) antagonist/5-HT(1A) agonist properties on PCP-induced social interaction deficits in the rat. Neuropharmacology. 2005; 49(7): 996-1006.
31. Benkert O, Muller-Siecheneder F, Wetzel H. Dopamine agonists in schizophrenia: a review. Eur Neuropsychopharmacol. 1995; 5 Suppl: 43-53.
32. Cuisiat S, et al. Towards a new generation of potential antipsychotic agents combining D2 and 5-HT1A receptor activities. J Med Chem. 2007; 50(4): 865-76. (Pubitemid 46332998)
33. Assie MB, et al. F15063, a potential antipsychotic with dopamine D2/D3 receptor antagonist, 5-HT1A receptor agonist and dopamine D4 receptor partial agonist properties: influence on neuronal firing and neurotransmitter release. Eur J Pharmacol. 2009; 607(1-3): 74-83.
34. Snigdha S, Neill JC. Improvement of phencyclidine-induced social behaviour deficits in rats: involvement of 5-HT1A receptors. Behav Brain Res. 2008; 191(1): 26-31.